NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

特應性皮炎藥物的全球市場(2020-2027)

Global Atopic Dermatitis Drugs Market - 2021-2028

出版商 DataM Intelligence 商品編碼 967421
出版日期 內容資訊 英文 180 Pages
商品交期: 約2個工作天內
價格
特應性皮炎藥物的全球市場(2020-2027) Global Atopic Dermatitis Drugs Market - 2021-2028
出版日期: 2021年06月14日內容資訊: 英文 180 Pages
簡介

推動全球特應性皮炎藥物市場增長的重要因素是加劇特應性皮炎的食物過敏。此外,某些肥皂,洗滌劑,香水等也會引起皮膚刺激。

在過去的幾年中,人們對疾病的治療方法的認識不斷提高,這也有助於獲得市場動力。政府提供主動性和有利的醫療報銷政策以提供更好和更實惠的治療方法可能會刺激市場。此外,針對性療法如Eucrisa和Dupixent的採用正在擴大,從而有利於市場。然而,治療劑的高成本會阻礙市場的增長。

本報告調查了全球特應性皮炎藥物市場,市場概況,對COVID-19影響的分析,按細分市場和地區進行的市場分析和預測,競爭情況分析,主要公司提供配置文件等。

目錄

第1章特應性皮炎藥物的全球市場:研究方法/範圍

  • 調查方法
  • 調查目的和範圍

第2章全球特應性皮炎治療市場:市場定義和概述

第3章全球特應性皮炎藥物市場:執行摘要

  • 市場細分:按藥品類別
  • 市場細分:按管理途徑
  • 市場細分:按最終用途
  • 市場細分:按地區

第4章全球特應性皮炎藥物市場:市場動態

  • 影響市場的因素
    • 促進因素
    • 抑制因素
    • 市場機會
    • 影響分析

第5章全球特應性皮炎藥物市場:行業分析

  • 波特的五力分析
  • 供應鏈分析
  • 價格分析
  • 監管分析
  • 贖回分析
  • 未滿足的需求

第6章特應性皮炎的全球市場:COVID-19分析

  • 市場上Covid-19的分析
    • COVID-19之前的市場情景
    • 當前COVID-19市場情況
    • COVID-19或更高版本或將來的方案
  • Covid-19價格動態
  • 供需範圍
  • 大流行期間與市場有關的政府舉措
  • 製造商的戰略計劃
  • 結論

第7章全球特應性皮炎治療市場:按□類型分類

  • 簡介
  • 市場規模分析和同比增長分析(%):按藥品類別細分
  • 市場吸引力指數:按藥品類別細分
    • 皮質類固醇
    • 鈣調神經磷酸□抑製劑
    • PDE4抑製劑
    • 生物製劑
    • 其他

第8章特應性皮炎的全球市場:按管理途徑

  • 簡介
  • 市場規模分析和同比增長分析(%):按管理途徑劃分
  • 市場吸引力指數:按管理途徑劃分
    • 局部
    • 注射
    • 口服

第9章全球特應性皮炎治療市場:最終用途

  • 簡介
  • 市場規模分析和同比增長分析(%):按應用
  • 市場吸引力指數:按應用
    • 醫院藥房
    • 零售藥房
    • 在線藥房
    • 其他

第10章全球特應性皮炎治療市場:按分銷渠道

  • 簡介
  • 市場規模分析和同比增長分析(%):按分銷渠道
  • 市場吸引力指數:按分銷渠道
    • 零售店
    • 網上商店

第11章全球特應性皮炎治療市場:按地區

  • 簡介
  • 市場規模分析和同比增長分析(%):按地區
  • 市場吸引力指數:按地區
  • 北美
    • 簡介
    • 特定地區的主要動態
    • 市場規模分析和同比增長分析(%):按藥品類別
    • 市場規模分析和同比增長分析(%):按管理途徑劃分
    • 市場規模分析和同比增長分析(%):按最終用途劃分
    • 市場規模分析和同比增長分析(%):按國家
  • 歐洲
  • 南美洲
  • 亞太地區
  • 中東/非洲

第12章全球特應性皮炎藥物市場:競爭形勢

  • 競爭情景
  • 市場定位/份額分析
  • 併購分析

第13章全球特應性皮炎治療市場:公司概況概述

  • Bayer
    • 公司簡介
    • 產品組合/說明
    • 主要亮點
    • 財務概覽
  • Mylan
  • Sanofi, Pfizer Inc.
  • Novartis International AG
  • Allergan PLC
  • Abbvie Inc.
  • Meda Pharmaceuticals
  • Valent Pharmaceutical Inc.
  • Encore Dermatology.
  • Regeneron Pharmaceuticals, Inc.

第14章過敏性皮炎的全球市場:重要考慮因素

第15章特應性皮炎的全球市場:DataM

  • 附錄
  • 關於我們的公司和服務
  • 聯繫我們

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMPH2742

Market Overview

The Global Atopic Dermatitis Drugs Market size was valued US$ XX billion in 2020 and is estimated to reach US$ XX billion by 2028, growing at a CAGR of XX % during the forecast period (2021-2028).

Atopic dermatitis is a widespread chronic inflammatory skin condition that can affect patients of all ages and result from a complex interplay of environmental, immunological, genetic, and pharmacologic factors. It's common in children but can occur at any age. Atopic dermatitis is long-lasting (chronic) and tends to flare periodically.

Market Dynamics

The global atopic dermatitis drug market growth is driven by the increasing prevalence of the allergic reactions, including food allergy, rising campaigns for awareness and high R&D in this field, these factors will drive the global atopic dermatitis drugs market growth in the forecast period.

Growing prevalence of food allergies that are exacerbating atopic dermatitis fuel the market growth

The increasing growth in the global atopic dermatitis drugs market is due to the growing prevalence of food allergies exacerbating atopic dermatitis. Allergy of any kind plays a vital role in the life of a person with atopic dermatitis. This condition generally flares when a person with atopic dermatitis disease is around substances that can cause allergic reactions. Primarily affecting children and infants, atopic dermatitis is estimated to account for around 10 to 20% of those suffering from eczema, according to the data of the American College of Allergy, Asthma & Immunology.

According to research, food allergy and severe atopic dermatitis coexist in approximately one-third of all children with atopic dermatitis. These food allergies are mainly caused by chicken eggs, cow's milk, peanuts, wheat, nuts, soy, and fish. Also, atopic dermatitis once appeared in childhood can exacerbate with time.

Additionally, skin irritants occur due to certain soaps, detergents, perfumes, etc. Thus, allergic reactions, mainly due to food, are among the significant factors increasing the burden of atopic dermatitis and driving the market growth.

Rise in awareness regarding the availability of treatments for the disease is driving the market growth

A rise in awareness regarding the availability of treatments for the disease has helped the market gain traction over the past few years. In addition, initiatives undertaken by governments to provide better and more affordable treatment and the presence of favorable reimbursement policies are likely to provide an upthrust to the market. Furthermore, growing acceptance of targeted therapies such as Eucrisa and Dupixent is also working in favor of the market.

For instance, approximately 60.0% of patients with AD develop symptoms in the first year, and roughly 90.0% of patients show symptoms by the age of five (atopic march). Disease onset after 30 is rare and may be caused by exposure to harsh environmental conditions.

On the other hand, affordable healthcare plans are being executed in all leading countries, influencing company price plans and adjustment possibilities. Nevertheless, there are various opportunities where a permanent cure for the disorder could be produced by the key players or develop a systematic treatment to recover affected patients from atopic eczema infections.

High cost of therapeutics is likely to hinder the market growth

However, the high cost of therapeutics is one of the critical roadblocks in the market's upward climb. Heightened cost consciousness, especially in emerging countries, is anticipated to hinder premium-pricing opportunities for upcoming AD drugs, particularly biologics. However, reasonable healthcare measures are being incorporated across all major regions, impacting companies' pricing strategies and reimbursement scenarios.

COVID-19 Impact Analysis

COVID-19, primarily a respiratory disease, causes severe illness, is not known. Exaggerated innate inflammatory and impaired adaptive immune responses have been observed. Atopic dermatitis is associated with multimorbidity and typified by innate and adaptive immune dysregulation, which is targeted by immunomodulatory therapies. In the context of COVID-19, the broad immune suppression conferred by conventional systemic agents, such as methotrexate, may reduce protective host antiviral immune responses. On the other hand, should treatment need to be paused in the pandemic, the longer half-life and individual pharmacokinetics of biological therapies will limit the speed of their systemic clearance. Although real-world observational data suggest an increased risk of severe infections with some agents,5, 6, their relative safety concerning COVID-19 is unknown-conversely, immunomodulators' theoretical protective role in attenuating a severe systemic inflammatory response to infection. Thus, the pandemic has hindered the growth of the atopic dermatitis drugs market in the forecast period.

Segment Analysis

Corticosteroids segment is expected to grow at the fastest CAGR during the forecast period (2021-2028)

Corticosteroids are referred to as cortisone-like medicines used as pain relief medication for inflammation in the body. These drugs are known to have reduced itching, swelling, allergic reactions, and redness. Additionally, these drugs are used as first-line treatment for different diseases, such as skin problems, severe allergies, arthritis, and asthma. Around 30 corticosteroid compounds have been licensed for atopic dermatitis treatment, of which hydrocortisone is considered the first. The rising innovations have led to the advent of counterfeit medicines and alternative drugs, such as immuno-modulators pimecrolimus and tacrolimus. However, these alternatives have pitfalls, such as selective effectivity and high cost. Hence, topical corticosteroids play a vital role in atopic dermatitis treatment.

Topical PDE4 inhibitor drugs have positive market growth in the forecast period. Healthcare companies in the atopic dermatitis drugs market are developing new drug agents to expand the treatment options for the disease. They are developing new moisturizers that confer skin-barrier protection, biologics, and lipid-replenishing topical drugs. Manufacturers are making these treatment options available at retail and hospital pharmacies. After several clinical trials, healthcare companies are introducing efficacious ointments that provide a result-oriented outcome in patients.

The topical route of administration (ROA) segment are expected to dominate the atopic dermatitis drugs market, by route of administration, during the forecast period

Topical ROA is the most effective treatment with minor side effects. These drugs are applied directly to the skin, like ointments or creams. Topical corticosteroids are the most widely prescribed medications for AD. They are often administered in combination with moisturizers or emollients for more effective results. The high incidence and prevalence of skin disease and increase in the incidence rate of bone disorders are driving the topical drugs market. The rise in painless treatments, such as topical patches, for chronic diseases is further driving the segment growth. For instance, in 2017, Dupixent's launched injectables in the AD therapeutic landscape. However, topicals are estimated to maintain their lead through 2022.

The oral segment has favorable market growth in the forecast period. The antibiotics given for oral treatment are also used for intravenous treatments. These antibiotics effectively manage atopic dermatitis, especially when the skin shows signs of bacterial infection such as weeping, bumps, crusting, or painful swelling (cellulitis).

Geographical Analysis

North America region holds the largest market share in the global atopic dermatitis drugs market

North America is expected to provide high business growth for the atopic dermatitis market over the forecast period. The factors, such as high treatment awareness among the patient population across the United States and Canada, healthcare infrastructure, early adoption of novel medications, better reimbursement policies, and increasing business partnerships of pharmaceutical companies with contract research organizations in the emerging markets, help the lucrative nature of this market in North America. Increasing incidence of atopic dermatitis, soaring treatment rate, and inflated drug prices are key trends augmenting revenue generation in the region. All such factors combine to add to the growth of the North American atopic dermatitis drugs market during the forecast period.

Competitive Landscape

The atopic dermatitis drugs market is moderately competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Bayer, Sanofi, Pfizer Inc., Novartis International AG, Allergan PLC, Abbvie Inc., Meda Pharmaceuticals, JW Pharmaceutical, Fuzhou FUL Fluid Equipment & Pharmaceutical Co., Ltd., Wuhan Disel Biotechnology Co., Ltd., and Qingdao Hiseeking Enterprises Co., Ltd. among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the atopic dermatitis drugs market globally.

Atopic Dermatitis Drugs Market Key Companies to Watch

JW Pharmaceutical

Overview: JW Pharmaceutical Corp. (formerly Choongwae Pharma) pharmaceutical firms in Korea with core competencies in IV solutions, antibiotics and anti-cancer treatments. JW is currently investigating targeted therapies in oncology, leveraging the collaborative research and development intensities from the JW Drug Discovery Center in Korea and the JW Theriac Corp in the US. JW Group consists of JW Pharmaceutical, JW Holdings, JW Medical, JW Industrial, JW ShinYak, JW Life Science, and JW Creagene.

Product Portfolio: The Company's portfolio comprises endocrinology, gastroenterology, oncology, cardiology, nephrology, urology and the general surgery therapeutic areas.

Key Development: In August 2018, JW Pharmaceutical and LEO Pharma A/S signed a licensing agreement for JWP's novel atopic dermatitis drug candidate, JW1601, under which, LEO Pharma, a global leader in medical dermatology, gained exclusive rights to develop and commercialize JW1601, globally, excluding South Korea.

Why Purchase the Report?

  • Visualize the composition of the atopic dermatitis drugs market segmentation by drug class, route of administration, and end user highlighting the key commercial assets and players.
  • Identify commercial opportunities in atopic dermatitis drugs market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of atopic dermatitis drugs market - level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The global atopic dermatitis drugs market report would provide an access to an approx. 61 market data table, 55 figures and 200 pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Market Segmentation

Global Atopic Dermatitis Drugs Market - By Drug class

  • Corticosteroids
  • Calcineurin Inhibitors
  • PDE4 inhibitors
  • Biologics
  • Other

Global Atopic Dermatitis Drugs Market - By Route of Administration

  • Topical
  • Injectable
  • Oral

Global Atopic Dermatitis Drugs Market -By End User

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

Global Atopic Dermatitis Drugs Market - By Region

  • North America
  • South America
  • Europe
  • Asia
  • Middle East & Africa

Table of Contents

1. Global Atopic Dermatitis Drugs Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Atopic Dermatitis Drugs Market - Market Definition and Overview

3. Global Atopic Dermatitis Drugs Market - Executive Summary

  • 3.1. Market Snippet By Drug class
  • 3.2. Market Snippet By Route of Administration
  • 3.3. Market Snippet by End User
  • 3.4. Market Snippet by Region

4. Global Atopic Dermatitis Drugs Market - Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Growing prevalence of food allergies that are exacerbating atopic dermatitis
      • 4.1.1.2. Rise in awareness regarding the availability of treatments for the disease
    • 4.1.2. Restraints:
      • 4.1.2.1. High cost of therapeutics is likely to hinder the market growth
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Atopic Dermatitis Drugs Market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Reimbursement Analysis
  • 5.6. Unmet Needs

6. Global Atopic Dermatitis Drugs Market - COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Global Atopic Dermatitis Drugs Market - By Drug class

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug class Segment
    • 7.1.2. Market Attractiveness Index, By Drug class Segment
  • 7.2. Corticosteroids*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 7.3. Calcineurin Inhibitors
  • 7.4. PDE4 inhibitors
  • 7.5. Biologics
  • 7.6. Other

8. Global Atopic Dermatitis Drugs Market - By Route of Administration

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 8.1.2. Market Attractiveness Index, By Route of Administration
  • 8.2. Topical*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 8.3. Injectable
  • 8.4. Oral

9. Global Atopic Dermatitis Drugs Market - By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), End User
    • 9.1.2. Market Attractiveness Index, By End User
  • 9.2. Hospital Pharmacies*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 9.3. Retail Pharmacies
  • 9.4. Online Pharmacies
  • 9.5. Others

10. Global Atopic Dermatitis Drugs Market - By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug class
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug class
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%),End User
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug class
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug class
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.7.1. China
      • 10.5.7.2. India
      • 10.5.7.3. Japan
      • 10.5.7.4. Australia
      • 10.5.7.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug class
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Global Atopic Dermatitis Drugs Market - Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking
  • 11.4. List of key companies to watch
  • 11.5. List of the company with disruptive technology
  • 11.6. List of start-up companies

12. Global Atopic Dermatitis Drugs Market- Company Profiles

  • 12.1. Bayer*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Sanofi
  • 12.3. Pfizer Inc.
  • 12.4. Allergan PLC
  • 12.5. Abbvie Inc.
  • 12.6. Meda Pharmaceuticals
  • 12.7. JW Pharmaceutical
  • 12.8. Fuzhou FUL Fluid Equipment & Pharmaceutical Co., Ltd.
  • 12.9. Wuhan Disel Biotechnology Co., Ltd.
  • 12.10. Qingdao Hiseeking Enterprises Co., Ltd.

LIST NOT EXHAUSTIVE

13. Global Atopic Dermatitis Drugs Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us